ZEISS MyoCare lenses
A better outlook on life.
Our first age-related myopia management portfolio with lens designs aimed to slow down the progression of myopia. MyoCare is backed by ZEISS innovation and more than a decade of experience in developing lenses to manage myopia progression.
Our complete age-related, myopia management portfolio consists of 2 lens designs.
ZEISS MyoCare lenses
Recommended for children younger than 10 years. Incorporating
- Cylindrical Annular Refractive Elements, C.A.R.E.® technology – aimed to deliver a “stop signal” to slow down progression of axial elongation. It consists of alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens.
- ZEISS ClearFocus design – aimed to remove the “growth signal”, the optimised back surface delivers the refractive correction as well as intended myopic defocus of the patient for all gaze directions.
-
- Central clear zone of 7 mm
- Mean additional surface power of +4.6 D
- Fill factor of 0.5
ZEISS MyoCare S lenses
Recommended for children 10 years and older. Incorporating:
- Cylindrical Annular Refractive Elements, C.A.R.E.® technology – aimed to deliver a “stop signal” to slow down progression of axial elongation. It consists of alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens.
- ZEISS ClearFocus design – aimed to remove the "growth signal", the optimised back surface delivers the refractive correction as well as intended myopic defocus of the patient for all gaze directions.
-
- Central clear zone of 9 mm
- Mean additional surface power of +3.8 D
- Fill factor of 0.5
Myopia is a worldwide concern
The prevalence of myopia across Europe is becoming more common
The prevalence of high myopia is increasing, leading to a higher risk of eye problems such as retinal damage that may even result in blindness.
The prevalence of myopia and risk of juvenile myopia progression is relatively low in Europe compared to Asia where it is a big concern. Still, myopia is becoming more common across the region, with a clear trend of higher myopia prevalence in the younger population.2 Certain lifestyle changes have also created conditions that trigger an earlier onset of myopia in children. Among school-aged children*, the prevalence of myopia in Europe is:
• 3%in preschool (6 years old),
• 11%in primary school (7–10 years old)
• 20–30%in secondary school (11–17 years old)
• 47% in young adults aged 25 to 29 years old, reaching peak prevalence.
One problem – many solutions.
Optical, medical and behavioural treatments.
Because of its multifactorial causes, there’s no one-and-only treatment for myopia. In fact, there are many treatment options on the market including optical, medical and behavioural treatments.
The choice of myopia treatments for children should be based on the age of onset, and axial length or refraction at a given age, along with knowledge of their individual rate of progression and overall risk profile.
Comprehensive myopia treatments include a combination of lifestyle advice, a refractive correction method for full-time use, and myopia control methods to reduce or eliminate further progression.
Orthokeratology for progressive myopia
Specialised rigid contact lenses are worn overnight to allow clear vision during the day. Corneal reshaping effectively corrects refractive errors while slowing down axial elongation. Its effects may vary from day to day.
Soft contact lenses
Dual-focus soft contact lens designs are worn during the day. The soft contact lenses feature concentric optical zones that simultaneously create foveal correction and retinal myopic defocus.
Spectacle lenses
The least invasive and most accessible method for correcting myopia. The advantage of special spectacle lens designs is that it corrects vision and controls the progression of myopia at the same time. New generation spectacle lenses utilise optical microstructures which positively contributes to myopia progression management. Spectacle lenses are easy to wear, affordable, and mostly well accepted and tolerated, making it the most favourable solution.
Pharmaceutical methods
This involves the application of pharmaceuticals. Pharmaceutical methods are reportedly effective in managing myopia progression.
Outdoor activities
Frequent outdoor activity is recommended to prevent or delay the onset of myopia. This equates to a minimum of 2 hours of intermittent outdoor time per day including additional outdoor time after school.
A new lens design.
Creating simultaneous competing defocus.
Our latest lens designed to manage progressive myopia in children, is built on more than a decade of ZEISS innovation and experience in myopia management, in collaboration with optical experts such as material and vision scientists, eye care practitioners and academics.
The design of ZEISS MyoCare lenses incorporates scientific concepts from proven scientific research, evidence-based learnings and effective treatments, including orthokeratology, soft multifocal contact lenses, science and the new generation of spectacles.
Finding the right balance with ZEISS C.A.R.E. technology.
The perfect combination of distinct optimisation parameters and a specific design.
An effective myopia mangement lens must overcome certain design challenges and find the optimum balance between myopia progression management and good vision. For this we have included the following in our ZEISS myopia management solutions:
- A central zone small enough to establish an effective functional zone projecting myopic defocus on the near periphery close to the fovea
- A mean addition surface power to induce the intended relative myopic defocus
- A carefully selected fill factor to deliver high efficacy while preserving good wearability
ZEISS ClearFocus design.
Addressing the constant movement of the eyes.
Spectacle lenses must consider the moving eye behind the lens to ensure that the intended correction and myopic defocus is maintained for all gaze angles.
With the ZEISS ClearFocus design, both the optimal refractive correction according to the patient’s refractive demands and the intended myopic defocus are maintained for all gaze directions.
This is important not only for distinct viewing behaviours through the central clear zone when pursuing a focused task, but also for unintended gazes and saccades to the lens periphery.
In addition to that, the ZEISS ClearFocus design effectively minimises the induction of hyperopic defocus as opposed to typical spherical single vision lenses.
ZEISS ClearFocus design aimed to effectively minimize the induction of hyperopic defocus.
The spherical error on spherical single vision lenses becomes obvious at about 10 mm distance from the lens centre, with increasing negative power towards the outer lens perimeter, thereby inducing hyperopic defocus.
In contrast to traditional spherical lens designs, ZEISS MyoCare lenses exhibit a flat and almost invariant spherical error throughout the lens, ensuring that the focus remains close to the intended focus shell, i.e., close to the retina. With increasing eccentricity from the lens centre, the spherical error even grows slightly more positive, inducing relative myopic defocus.
In summary, the ZEISS ClearFocus design featured in MyoCare® lenses effectively minimizes unwanted hyperopic defocus for all viewing angles.
A new approach to measure effectiveness.
Emmetropic progression ratio.
Each myopia progression management intervention has its own advantages and disadvantages, however each option pursues a common target:To slow down myopia progression.
Developmental milestones offer important insights into a child’s developmental health. Reaching specific milestones at a given age shows a child is developing as expected. A comparison between the normal physiological growth and the patient’s current growth is needed to observe whether there is some type of non-physiological deviation present.
The ZEISS MyoCare designs show an average emmetropic progression ratio for axial length of up to 86% for children aged 10-12 years and 63% for children aged 7-9 years.
Age-normal physiological growth curves.
It is not different when it comes to vision development. Here the focus is on the difference between the physiological elongation of the eye and the non-physiological (myopic) elongation, in other words, how far the child’s current status is from the age-normal physiological growth for emmetropic children.
The aim is to follow or to be as close as possible to the age-normal physiological growth curves of emmetropic children.
The physiological emmetropic curve in the graph acts as the baseline value used as the reference to evaluate treatment effectiveness of our myopic progression intervention, MyoCare.
Emmetropic progression ratio as a percentage of effectivity.
Once the treatment baseline is established, the emmetropic progression ratio is the parameter for the indication of how close children with the intervention are coming to the emmetropic growth curve in contrast to the myopic growth curve.
The aim is to get the absolute reduction curve of the myopia management solution (blue line) as close as possible to the physiological emmetropisation curve (black line) in contrast to the myopic curve (red line).
The emmetropic growth ratio is calculated with a specific formula.
ZEISS MyoCare designs effectively slow down myopia progression to come closer to the physiological growth curve.
New age-related myopia management lens solutions
ZEISS MyoCare and ZEISS MyoCare S
Different interventions have different effects. The same goes for the two different designs in the MyoCare portfolio. According to research results, there is a significant group difference in axial length and spherical equivalent refraction change between the untreated group wearing single vision correction and the treatment group wearing ZEISS MyoCare lenses. Based on this it is recommended to have separate designs for separate age groups:
- MyoCare® for children younger than 10 years
- MyoCare® S for children 10 years and older
Why MyoCare® lenses should be your choice.
Vision as good as with single vision lenses.
With a lens that is effective in managing myopia progression in children, it makes sense to also look at the comfort and vision experienced by the wearer. This is why the voices of the children are important.
98% of children claimed that their distance and near vision is very good when wearing ZEISS MyoCare designs, and 100% of children adapted to the lenses within one day.
Fun should never be restricted for kids! When wearing ZEISS MyoCare lenses children can still enjoy activities such as reading, outdoor play and sports. With MyoCare, you can provide your young patients with the best care.
ZEISS MyoCare innovations.
New lens designs to deliver simultaneous competing defocus.
A myopia management lens design, aimed to slow down the progression of myopia in children is built on 2 pillars.
ZEISS C.A.R.E. technology (Cylindrical Annular Refractive Elements)
Alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens. These microstructures deliver a “stop signal” to slow down progression of axial elongation.
ZEISS ClearFocus design
Aimed to remove the growth signal, the optimised back surface minimises hyperopic defocus in the periphery of the lens. Both the refractive correction as well as intended myopic defocus of the patient is maintained for all gaze directions. This technology supports the effectivity and wearability of ZEISS MyoCare lenses.